entacapone vs Trigel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: COMT · full Parkinson's Disease pipeline

entacapone · Comtess

Marketed by Orion Corporation and partners

Approved in Parkinson's Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT04246437 (registry estimate)

No aligned efficacy figure on record for this race.

Trigel · Lecigon

Marketed by STADA Arzneimittel and partners

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT02448914 · Phase 1 · completed

This trial had randomized treatment order and an active comparator, and it reached a statistically significant result for its primary measure, but it was not blinded, enrolled only 11 patients, and measured drug blood levels rather than a clinical symptom or functional outcome, so it demonstrates pharmacokinetic exposure rather than a proven clinical benefit.

Next expected readout: September 2030 · NCT07151378 (registry estimate)

Reported efficacy

Dose Adjusted Area Under the Curve (AUC) (0-14h) for Levodopa (During 14 h infusion on 2 consecutive days): Dose Adjusted Area Under the Curve (AUC) (0-14h) for Levodopa (During 14 h infusion on 2 consecutive days): TRIGEL 40.6 h*ng/mL/mg (range 22.3 to 69.4) | Duodopa 29.4 h*ng/mL/mg (range 21.7 to 52.8) (met)

Result source: NCT02448914

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointentacaponeTrigel
OFF time, change—Not posted · NCT00134966—Trial running · NCT07151378
ON time without troublesome dyskinesia, change—Not posted · NCT00134966—Trial running · NCT07151378
UPDRS Part III, change-3.7 vs -1.8vs Carbidopa/Levodopawk 4 · n 161NCT00219284
3 other results
  • -3.6 vs -3.7 wk 8 · n 146 · Phase 4 · secondary NCT00219284
  • -3.6 vs -3.3 n 176 · Phase 4 · secondary NCT00219284
  • -4 vs -1.4 wk 12 · n 35 · Phase 4 · secondary NCT00391898
—Trial running · NCT07151378
MDS-UPDRS Part II, change—Not posted · NCT00134966—Trial running · NCT07151378

OFF time, change

entacapone
—Not posted · NCT00134966
Trigel
—Trial running · NCT07151378

ON time without troublesome dyskinesia, change

entacapone
—Not posted · NCT00134966
Trigel
—Trial running · NCT07151378

UPDRS Part III, change

entacapone
-3.7 vs -1.8vs Carbidopa/Levodopawk 4 · n 161NCT00219284
3 other results
  • -3.6 vs -3.7 wk 8 · n 146 · Phase 4 · secondary NCT00219284
  • -3.6 vs -3.3 n 176 · Phase 4 · secondary NCT00219284
  • -4 vs -1.4 wk 12 · n 35 · Phase 4 · secondary NCT00391898
Trigel
—Trial running · NCT07151378

MDS-UPDRS Part II, change

entacapone
—Not posted · NCT00134966
Trigel
—Trial running · NCT07151378
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. entacapone: 4 of 4 rows · Trigel: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricentacaponeTrigel
Dropout rate
24.4%a
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
23.9%
NCT00391898 · Phase 4 · registry result, not featured evidence
—
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
—
NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1
Discontinued due to AEs
14.4%a
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
6.5%
NCT00391898 · Phase 4 · registry result, not featured evidence
—
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
—
NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1
Serious AEs
4.4%a
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
2.2%
NCT00391898 · Phase 4 · registry result, not featured evidence
0%
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1
Most frequent reported AEs
a
nausea 17.2%
diarrhoea 16.1%
dizziness 8.9%
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
dyskinesia 15.6%
anxiety 11.1%
retching 6.7%
NCT00391898 · Phase 4 · registry result, not featured evidence
back pain 12.5% (placebo 0%)
pain in extremity 12.5% (placebo 9.1%)
abdominal pain lower 0% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
headache 27.3%
dizziness 18.2%
injection site haematoma 9.1%
NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

entacapone

UPDRS Part III -3.7 vs -1.8 Carbidopa/Levodopa score @ 4wk
absolute change · score
NCT00219284 · Phase 4 · registry result, not featured evidence
show 3 more results
-3.6 vs -3.7 Carbidopa/Levodopa score @ 8wk
NCT00219284 · Phase 4 · registry result, not featured evidence
-3.6 vs -3.3 Carbidopa/Levodopa score
NCT00219284 · Phase 4 · registry result, not featured evidence
-4 vs -1.42 Levodopa/Carbidopa score @ 12wk
NCT00391898 · Phase 4 · registry result, not featured evidence
Pdqol -0.4 vs 1.1 Carbidopa/Levodopa score @ 4wk
absolute change · score
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
-2.5 vs -1.1 Carbidopa/Levodopa score @ 8wk
NCT00219284 · Phase 4 · registry result, not featured evidence
-1.3 vs 0.2 Carbidopa/Levodopa score
NCT00219284 · Phase 4 · registry result, not featured evidence
PDQ-39 -1.7 vs 0.8 Carbidopa/Levodopa score @ 4wk
absolute change · score
NCT00219284 · Phase 4 · registry result, not featured evidence
show 3 more results
-5.8 vs -1.9 Carbidopa/Levodopa score @ 8wk
NCT00219284 · Phase 4 · registry result, not featured evidence
-2.8 vs 0.4 Carbidopa/Levodopa score
NCT00219284 · Phase 4 · registry result, not featured evidence
6.3 vs 0.8 Levodopa/Carbidopa score @ 12wk
NCT00391898 · Phase 4 · registry result, not featured evidence
UPDRS Part II ADL -2.5 vs -0.5 Levodopa/Carbidopa score @ 12wk
absolute change · score
NCT00391898 · Phase 4 · registry result, not featured evidence
UPDRS Part I -0.5 vs -0.2 Levodopa/Carbidopa score @ 12wk
absolute change · score
NCT00391898 · Phase 4 · registry result, not featured evidence
UPDRS Part IV -0.6 vs -0.1 Levodopa/Carbidopa score @ 12wk
absolute change · score
NCT00391898 · Phase 4 · registry result, not featured evidence

Trigel

Functional ON Time 91.7% (n=11) vs 91% (n=11) Duodopa
absolute value · percentage points
NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: entacapone's landscape · Trigel's landscape